Log In
BCIQ
Print this Print this
 

crizanlizumab (SEG101) (formerly SelG1)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHumanized mAb against P selectin (SELP; CD62P)
Molecular Target P selectin (SELP) (CD62P)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationSickle cell disease
Indication DetailsPrevent or reduce sickle cell-related pain crises; Treat sickle cell disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$665.0M

$10.0M

$415.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/21/2016

$665.0M

$10.0M

$415.0M

Get a free BioCentury trial today